DE69922009D1 - Imidazolverbindungen und ihre verwendung als adenosindeaminase-inhibitoren - Google Patents

Imidazolverbindungen und ihre verwendung als adenosindeaminase-inhibitoren

Info

Publication number
DE69922009D1
DE69922009D1 DE69922009T DE69922009T DE69922009D1 DE 69922009 D1 DE69922009 D1 DE 69922009D1 DE 69922009 T DE69922009 T DE 69922009T DE 69922009 T DE69922009 T DE 69922009T DE 69922009 D1 DE69922009 D1 DE 69922009D1
Authority
DE
Germany
Prior art keywords
hydroxy
optionally substituted
adenosine deaminase
protected
imidazole compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69922009T
Other languages
English (en)
Other versions
DE69922009T2 (de
Inventor
Tadashi Terasaka
Katsuya Nakamura
Nobuo Seki
Masako Kuno
Susumu Tsujimoto
Akihiro Sato
Isao Nakanishi
Takayoshi Kinoshita
Nobuya Nishio
Hiroyuki Okumura
Kiyoshi Tsuji
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPP4840A external-priority patent/AUPP484098A0/en
Priority claimed from AUPP7355A external-priority patent/AUPP735598A0/en
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of DE69922009D1 publication Critical patent/DE69922009D1/de
Application granted granted Critical
Publication of DE69922009T2 publication Critical patent/DE69922009T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
DE69922009T 1998-07-23 1999-07-22 Imidazolverbindungen und ihre verwendung als adenosindeaminase-inhibitoren Expired - Lifetime DE69922009T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPP484098 1998-07-23
AUPP4840A AUPP484098A0 (en) 1998-07-23 1998-07-23 Novel imidazole compounds
AUPP7355A AUPP735598A0 (en) 1998-11-27 1998-11-27 Novel imidazole compounds
AUPP735598 1998-11-27
PCT/JP1999/003939 WO2000005217A1 (en) 1998-07-23 1999-07-22 Imidazole compounds and their use as adenosine deaminase inhibitors

Publications (2)

Publication Number Publication Date
DE69922009D1 true DE69922009D1 (de) 2004-12-23
DE69922009T2 DE69922009T2 (de) 2005-04-07

Family

ID=25645831

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69922009T Expired - Lifetime DE69922009T2 (de) 1998-07-23 1999-07-22 Imidazolverbindungen und ihre verwendung als adenosindeaminase-inhibitoren

Country Status (16)

Country Link
US (1) US6359145B1 (de)
EP (1) EP1098885B9 (de)
JP (1) JP4525883B2 (de)
KR (1) KR100429754B1 (de)
CN (1) CN1291979C (de)
AT (1) ATE282599T1 (de)
BR (1) BR9912684A (de)
CA (1) CA2338305A1 (de)
DE (1) DE69922009T2 (de)
ES (1) ES2234269T3 (de)
HK (1) HK1041264B (de)
HU (1) HUP0103303A3 (de)
MX (1) MXPA01000549A (de)
PT (1) PT1098885E (de)
RU (1) RU2243220C2 (de)
WO (1) WO2000005217A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP921299A0 (en) 1999-03-15 1999-04-15 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
US6103702A (en) * 1999-05-24 2000-08-15 Board Of Trustees Of The University Of Illinois Use of adenosine deaminase inhibitors to treat systemic inflammatory response syndrome
AUPQ515700A0 (en) * 2000-01-19 2000-02-10 Fujisawa Pharmaceutical Co., Ltd. Imidazole compounds
AUPR636301A0 (en) * 2001-07-13 2001-08-02 Fujisawa Pharmaceutical Co., Ltd. Imidazole compounds
AUPS058102A0 (en) * 2002-02-15 2002-03-14 Fujisawa Pharmaceutical Co., Ltd. Imidazole compounds
US20040175804A1 (en) * 2003-03-04 2004-09-09 Skonezny Paul M. Process for preparing dideoxyinosine using adenosine deaminase enzyme
TW200815388A (en) * 2006-04-18 2008-04-01 Wyeth Corp Chromane and chromene derivatives and uses thereof
EP1859800B1 (de) * 2006-05-23 2009-12-30 MedDEV Inc. Imidazolcarbonsäurealkylester-haltiges Medikament zur Behandlung neurodegenerativer Erkrankungen
US8314136B1 (en) 2006-05-23 2012-11-20 MedDEV, Inc. Method for treatment of alzheimer's disease and autism spectrum disorders
EP2167474A1 (de) * 2007-06-11 2010-03-31 Valletta Health IP EE B.V. Zur behandlung von mit dem immunsystem in zusammenhang stehenden und entzündlichen krankheiten geeignete urocaninsäurederivate
JP5454458B2 (ja) * 2010-11-25 2014-03-26 信越化学工業株式会社 ポジ型レジスト材料及びパターン形成方法
CN108318594A (zh) * 2018-01-12 2018-07-24 上海中医药大学 一种液相色谱串联质谱法测定腺苷脱氨酶活性及筛选其抑制剂的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906965D0 (en) * 1989-03-28 1989-05-10 Schering Agrochemicals Ltd Fungicides
DE69401486T2 (de) * 1993-11-12 1997-04-30 Ishihara Sangyo Kaisha Verfahren zur Herstellung 2-cyanoimidazol Derivate
US5703084A (en) * 1996-07-15 1997-12-30 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Adenosine deaminase inhibitors

Also Published As

Publication number Publication date
HUP0103303A3 (en) 2002-09-30
MXPA01000549A (es) 2002-04-08
HUP0103303A2 (hu) 2002-04-29
US6359145B1 (en) 2002-03-19
ATE282599T1 (de) 2004-12-15
CA2338305A1 (en) 2000-02-03
HK1041264A1 (en) 2002-07-05
PT1098885E (pt) 2005-01-31
CN1291979C (zh) 2006-12-27
WO2000005217A1 (en) 2000-02-03
DE69922009T2 (de) 2005-04-07
ES2234269T3 (es) 2005-06-16
RU2243220C2 (ru) 2004-12-27
EP1098885A1 (de) 2001-05-16
KR20010072037A (ko) 2001-07-31
JP4525883B2 (ja) 2010-08-18
CN1319095A (zh) 2001-10-24
KR100429754B1 (ko) 2004-05-03
JP2002521369A (ja) 2002-07-16
EP1098885B1 (de) 2004-11-17
BR9912684A (pt) 2001-05-02
EP1098885B9 (de) 2005-05-18
HK1041264B (zh) 2007-08-17

Similar Documents

Publication Publication Date Title
ATE253545T1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
TNSN07281A1 (en) Pyrazole derivatives for the inhibition of cdk's and gsk's
DK1070056T3 (da) Phthalazinon-PDE III/IV-inhibitorer
DE50302975D1 (de) Neue xanthinderivate, deren herstellung und deren verwendung als arzneimittel
BRPI0409938A (pt) derivados de azetidinacarboxamida e seu uso em terapia
IL114315A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same for inhibiting phosphodiesterase IV
ATE248175T1 (de) Epothilonderivate und ihre verwendung als antitumormittel
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
NO20060665L (no) N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer
NO20062633L (no) Pyrazolderivater som proteinkinasemodulatorer
EP1731523A4 (de) Thiazolopyrimidinderivat
DE69425162D1 (de) 4,5-diaryloxazol-derivate
NO20060664L (no) N-substituerte benzimidazolyl C-kit inhibitorer
DE69922009D1 (de) Imidazolverbindungen und ihre verwendung als adenosindeaminase-inhibitoren
TR200201205T2 (tr) N-ikame edilmiş karbamoiloksialkil-azolyum türevleri.
DE60027435D1 (de) Substituierte 2-arylbenzazole und ihre verwendung als antitumorale mittel
AU2003250471A8 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
ATE291018T1 (de) Pyrazol verbindungen und ihre verwendung
DK1042319T3 (da) Dihydrobenzofuraner
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
DE60036558D1 (de) Phthalazinon-derivate als pde 4 hemmer
ATE247660T1 (de) Furopyridinderivate und ihre therapeutische verwendung
ATE238274T1 (de) Naphthalin derivate
ATE246174T1 (de) Tosylprolin-derivate als thymidylat-synthase inhibitoren
BR0308935A (pt) Inibidor de fosfodiesterase iv contendo derivado de piridilacrilamida

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ASTELLAS PHARMA INC., TOKIO/TOKYO, JP